health pharma news today obesity drugs glp-1 Could weight-loss eat the world? GLP‑1 real‑world data for obesity:

Cost savings should be weighed against the security of data that can be stored for longer periods of time, so that peptide integrity is maintained throughout the study timeline

Am J Physiol Endocrinol Metab 305 , E13671374, (2013)

So those indirect winds we are starting to look at like, wow, there's some benefit to your brain as well

Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments that have reshaped the obesity market

PLoS One 11 (11), 01661255e166223

The most common concomitant glucose-lowering medications were metformin (84%) and basal insulin (23%)